Compile Data Set for Download or QSAR
Report error Found 532 Enz. Inhib. hit(s) with all data for entry = 11528
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624479((2-(1-(6,7-dimethoxyquinazolin-4-yl)piperidin- 4-y...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624486(6,7-dimethoxy-4-(2-(S-methylsulfonimidoyl)- 1,2,3,...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624489(6-fluoro-7-methoxy-4-(4-(2-(S- methylsulfonimidoyl...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624499(8-(6,7-dimethoxyquinazolin-4-yl)-2-(S- methylsulfo...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624500(US11780849, Compound 54a)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624501(US11780849, Compound 54b)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624502(8-(7-methoxyquinolin-4-yl)-2-(S- methylsulfonimido...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624503(US11780849, Compound 55a)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624507(cyclopropyl(imino)(4-((7-methoxyquinolin-4- yl)oxy...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624508(US11780849, Compound 60a)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624513(imino(4-(((7-methoxyquinolin-4- yl)oxy)methyl)phen...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624514(US11780849, Compound 75a)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624520(imino(4-((7-methoxyquinolin-4- yl)oxy)phenyl)(meth...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624521(US11780849, Compound 80a)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624525(N-((1-(6,7-dimethoxyquinazolin-4- yl)piperidin-4- ...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624530(ethyl(imino)(4-((7-methoxyquinolin-4- yl)oxy)pheny...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624532(US11780849, Compound 103b)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624533({4-[(6-fluoro-7-methoxyquinolin-4- yl)oxy]phenyl}(...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624534(US11780849, Compound 114a)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624541([cyclopropyl({4-[(6-fluoro-7- methoxyquinolin-4-yl...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624542(US11780849, Compound 120a)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624556(imino(3-{[(7-methoxyquinolin-4- yl)oxy]methyl}phen...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624557(US11780849, Compound 133a)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624560((3-fluoro-4-{[(7-methoxyquinolin-4- yl)oxy]methyl}...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624561((4-{[6-fluoro-7-methoxyquinolin-4- yl)oxy]methyl}p...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624566({2-[1-(6-chloro-7-methoxyquinolin-4- yl)piperidin-...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624569({2-[1-(6-chloro-7-methoxyquinazolin-4- yl)piperidi...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624579({2-[1-(6-fluoro-7-methoxyquinolin-4- yl)piperidin-...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624580({2-[1-(6,7-dimethoxycinnolin-4-yl)piperidin- 4-yl]...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624581(6-chloro-4-(4-{2-[imino(methyl)oxo-lambda6- sulfan...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624592([7-(6,7-dimethoxyquinolin-4-yl)-1,2,3,4- tetrahydr...)
Affinity DataIC50: 10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624500(US11780849, Compound 54a)
Affinity DataIC50: 340nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624542(US11780849, Compound 120a)
Affinity DataIC50: 460nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624557(US11780849, Compound 133a)
Affinity DataIC50: 500nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624475((4-((6,7-dimethoxyquinolin-4- yl)oxy)phenyl)(imino...)
Affinity DataIC50: 505nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624477((S)-(4-((6,7-dimethoxyquinolin-4- yl)oxy)phenyl)(i...)
Affinity DataIC50: 505nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624480((2-fluoro-4-((7-methoxyquinolin-4- yl)oxy)phenyl)(...)
Affinity DataIC50: 505nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624481((3-fluoro-4-((7-methoxyquinolin-4- yl)oxy)phenyl)(...)
Affinity DataIC50: 505nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624482((4-(((6,7-dimethoxyquinazolin-4- yl)oxy)methyl)phe...)
Affinity DataIC50: 505nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624483((4-((6,7-dimethoxyquinazolin-4- yl)oxy)phenyl)(imi...)
Affinity DataIC50: 505nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624490(6-fluoro-7-methoxy-4-(4-(S- methylsulfonimidoyl)ph...)
Affinity DataIC50: 505nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624491(US11780849, Compound 44a)
Affinity DataIC50: 505nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624493(6-methoxy-4-(4-(S- methylsulfonimidoyl)phenoxy)qui...)
Affinity DataIC50: 505nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624495(7-methoxy-4-(2-(S-methylsulfonimidoyl)- 1,2,3,4-te...)
Affinity DataIC50: 505nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624498(7-methoxy-4-(2-(S-methylsulfonimidoyl)-2,7- diazas...)
Affinity DataIC50: 505nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624504(US11780849, Compound 55b)
Affinity DataIC50: 505nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624505(8-methoxy-4-(4-(2-(S- methylsulfonimidoyl)ethyl)pi...)
Affinity DataIC50: 505nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624506(8-methoxy-4-(4-(S- methylsulfonimidoyl)phenoxy)qui...)
Affinity DataIC50: 505nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624509(US11780849, Compound 60b)
Affinity DataIC50: 505nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM624510(imino(2-(1-(7-methoxyquinolin-4-yl)piperidin- 4-yl...)
Affinity DataIC50: 505nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 532 total ) | Next | Last >>
Jump to: